Replies to post #124029 on Biotech Values

[DewDiligence]

At what point would TEVA start to get interesting even with the threat of generic Copaxone and no Teva Lovenox? At $40? At $35?

The answer depends on whether you think Teva will meet the 2015 sales and earnings guidance set forth in #msg-56956538.

Do you think they can?